Please provide your email address to receive an email when new articles are posted on . Baxdrostat demonstrated significant BP lowering in patients with treatment-resistant hypertension. AstraZeneca ...

Findings showed treatment with lorundrostat resulted in statistically significant reductions in systolic blood pressure compared with placebo. Topline data were announced from a phase 3 trial ...

MADRID, Spain—Baxdrostat (AstraZeneca), an investigational aldosterone synthase inhibitor, provides substantial reductions in blood pressure when added to background therapy in patients with ...

Amiloride is noninferior to spironolactone in lowering home systolic blood pressure over 12 weeks in patients with resistant hypertension. The finding is from the SPironolactone Versus Amiloride for ...

Lorundrostat (Mineralys Therapeutics), a novel aldosterone synthase inhibitor, can substantially lower blood pressure in patients with uncontrolled and treatment-resistant hypertension, according to ...

A new drug has shown unprecedented promise in lowering blood pressure and preventing the progression of kidney disease for people with hard-to-treat hypertension. The medication, baxdrostat, reduces ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...

Numbers in parentheses (%) indicate the percentage of patients with follow-up measurements. An ellipsis indicates that the information is unavailable. eGFR: Estimated ...